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Synopsis 
 
Unravelling the regulators of translation and replication of  
Hepatitis C virus 
 
Hepatitis C virus (HCV) is a positive sense, single stranded RNA virus belonging to 
the genus Hepacivirus and the family Flaviviridae. It infects human liver cells 
predominantly. Although, the treatment with α interferon and ribavirin can control 
HCV in some cases, they fail to achieve sustained virological response in others, 
thus emphasizing the need of novel therapeutic targets. 
 The viral genome is 9.6 kb long consisting of a 5’ untranslated region (5’UTR), a 
long open reading frame (ORF) that encodes the viral proteins and the 3’ 
untranslated region (3’UTR). The 5’UTR contains a cis acting element, the internal 
ribosome entry site (IRES) that mediates the internal initiation of translation. The 
HCV 5’UTR is highly structured and consists of four major stem-loops (SL) and a 
pseudoknot structure. HCV proteins are synthesized by the IRES mediated 
translation of the viral RNA, which is the initial obligatory step after infection. The 
viral proteins are synthesized in the form of a long continuous chain of proteins, the 
polyprotein, which is then processed by the host cell and the viral proteases. Once 
viral proteins are synthesized sufficiently, the viral RNA is replicated. However the 
mechanism of switch from translation to viral RNA replication is not well understood. 
Several host proteins as well as the viral proteins help in the completion of various 
steps in the HCV life cycle. In this thesis, the role of two such factors in HCV RNA 
translation and replication has been characterized and exploited to develop anti-HCV 
peptides. 
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The HCV proteins are categorized into two major classes based on the functions 
broadly: the non structural and the structural proteins. HCV NS3 protein (one of the 
viral non structural proteins) plays a central role in viral polyprotein processing and 
RNA replication. In the first part of the thesis, it has been demonstrated that the NS3 
protease (NS3pro) domain alone can specifically bind to HCV-IRES RNA, 
predominantly in the SLIV region. The cleavage activity of the NS3 protease domain 
is reduced upon HCV-RNA binding owing to the participation of the catalytic triad 
residue (Ser 139) in this RNA protein interaction. More importantly, NS3pro binding to 
the SLIV region hinders the interaction of La protein, a cellular IRES-trans acting 
factor required for HCV IRES-mediated translation, thus resulting in the inhibition of 
HCV-IRES activity. Moreover excess La protein could rescue the inhibition caused 
by the NS3 protease. Additionally it was observed that the NS3 protease and human 
La protein could out-compete each other for binding to the HCV SL IV region 
indicating that these two proteins share the binding region near the initiator AUG 
which was further confirmed using RNase T1 foot printing assay. Although an over 
expression of NS3pro as well as the full length NS3 protein decreased the level of 
HCV IRES mediated translation in the cells, replication of HCV RNA was enhanced 
significantly. These observations suggested that the NS3pro binding to HCV IRES 
reduces translation in favour of RNA replication. The competition between the host 
factor (La) and the viral protein (NS3) for binding to HCV IRES might contribute in 
the regulation of the molecular switch from translation to replication of HCV.  
In the second part the interaction of NS3 protease and HCV IRES has been 
elucidated in detail and the insights obtained were used to target HCV RNA function. 
Computational approach was used to predict the putative amino acid residues within 
the protease that might be involved in the interaction with the HCV IRES.  Based on 
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the predictions a 30-mer peptide (NS3proC-30) was designed from the RNA binding 
region. This peptide retained the RNA binding ability and also inhibited IRES 
mediated translation. The NS3proC-30 peptide was further shortened to 15-mer 
length (NS3proC-C15) and demonstrated ex vivo its ability to inhibit translation as well 
as replication. Additionally, its activity was tested in vivo in a mice model by 
encapsulating the peptide in Sendai virus based virosome followed by preferential 
delivery in mice liver. This virosome derived from Sendai virus F protein has terminal 
galactose moiety that interacts with the asialoglycoprotein receptor on the 
hepatocytes leading to membrane fusion and release of contents inside the cell. 
Results suggested that this peptide can be used as a potent anti-HCV agent. 
 It has been shown earlier from our laboratory, that La protein interacts with HCV-
IRES near initiator AUG at GCAC motif by its central RNA recognition motif, the 
RRM2 (residues 112-184). A 24 mer peptide derived from this RRM2 of La (LaR2C) 
retained RNA binding ability and inhibited HCV RNA translation. NMR spectroscopy 
of the HCV-IRES bound peptide complex revealed putative contact points, mutations 
at which showed reduced RNA binding and translation inhibitory activity. The 
residues responsible for RNA recognition were found to form a turn in the RRM2 
structure. A 7-mer peptide (LaR2C-N7) comprising this turn showed significant 
translation inhibitory activity. The bound structure of the peptide inferred from 
transferred NOE (Nuclear Overhauser Effect) experiments suggested it to be a β-
turn. Interestingly, addition of hexa-arginine tag enabled the peptide to enter Huh7 
cells and showed inhibition HCV-IRES function. More importantly, the peptide 
significantly inhibited replication of HCVRNA. Smaller forms of this peptide however 
failed to show significant inhibition of HCV RNA functions suggesting that the 7-mer 
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peptide as the smallest but efficient anti-HCV peptide from the second RNA 
recognition motif of the human La protein. 
Further, combinations of the LaR2C-N7 and NS3proC-C15 peptide showed better 
inhibitory activity. Both the peptides were found to be interacting at similar regions of 
SLIV around the initiator AUG. The two approaches have the potential to block the 
HCV RNA-directed translation by targeting the host factor and a viral protein, and 
thus can be tried in combination as a multi drug approach to combat HCV infection. 
Taken together, the study reveals important insights about the complex regulation of 
the HCV RNA translation and replication by the host protein La and viral NS3 
protein. The interaction of the NS3 protein with the SLIV of HCV IRES leads to 
dislodging of the human La protein to inhibit the translation in favour of the RNA 
replication. These two proteins thus act as the regulators of the translation and the 
replication of viral RNA. The peptides derived from these regulators in turn regulate 
the functions of these proteins and inhibit the HCV RNA functions.  
